机译:基于新型脲基丙基酰胺的N-甲酰肽受体2(FPR2)激动剂,其具有神经系统疾病的潜在应用,其特征是神经炎症的
Dipartimento di Farmacia - Scienze del Farmaco Università degli Studi di Bari Aldo Moro;
Department of Experimental Neuroendocrinology Institute of Pharmacology Polish Academy of Sciences;
Dipartimento di Farmacia - Scienze del Farmaco Università degli Studi di Bari Aldo Moro;
Department of Microbiology and Immunology Montana State University;
Department of Microbiology and Immunology Montana State University;
Department of Experimental Neuroendocrinology Institute of Pharmacology Polish Academy of Sciences;
Dipartimento di Oncologia Università di Torino;
Dipartimento di Farmacia - Scienze del Farmaco Università degli Studi di Bari Aldo Moro;
Department of Microbiology and Immunology Montana State University;
Department of Experimental Neuroendocrinology Institute of Pharmacology Polish Academy of Sciences;
Dipartimento di Farmacia - Scienze del Farmaco Università degli Studi di Bari Aldo Moro;
Formyl peptide receptor 2; Neuroinflammation; Ureidopropanamides; Microglia; Metabolic stability; Blood-brain barrier permeation;
机译:基于新型脲基丙基酰胺的N-甲酰肽受体2(FPR2)激动剂,其具有神经系统疾病的潜在应用,其特征是神经炎症的
机译:基于Ureidoplapana酰胺支架的官能N-甲酰基肽受体2(FPR2)拮抗剂具有保护相关氧化应激的可能性
机译:5-羟色胺5-HT7受体药物:中枢神经系统疾病的结构活性关系和潜在的治疗应用。
机译:制作受体亚型选择性肽激动剂和拮抗剂的设计策略 - Melanocortie受体系统
机译:人疱疹病毒6的中枢神经系统感染和CD46病毒受体参与介导的神经炎症机制。
机译:基于Ureidopropanamide的新型N-甲酰基肽受体2(FPR2)激动剂潜在应用于神经炎症为特征的中枢神经系统疾病。
机译:基于新的脲基丙基酰胺基N-甲酰基肽受体2(FPR2)激动剂,其具有神经系统疾病的潜在应用,其特征是神经炎症的